KRAS and non-small cell lung carcinoma: Together with evidence that “vertical” RAF/MEK blockade was synthetically lethal in KRAS-mut contexts [19], such background prompted us to select NSCLC and PDAC, two diseases where KRAS mutations are frequent and bear important clinical consequences, as the main target of our analysis.